<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00479596</url>
  </required_header>
  <id_info>
    <org_study_id>BTX0621</org_study_id>
    <nct_id>NCT00479596</nct_id>
  </id_info>
  <brief_title>This is a Prospective, Randomized, Double-Blind Study Comparing Intravesical Injection of Botox® to Placebo.</brief_title>
  <acronym>BTX0621</acronym>
  <official_title>Safety and Efficacy Study of Intradetrusor Injections of Botox® for the Treatment of Urinary Incontinence Secondary to Benign Prostatic Obstruction (BTX0621)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Urological Sciences Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Urological Sciences Research Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study will investigate the comparative efficacy, safety and patient satisfaction&#xD;
      of intradetrusor injections BOTOX® injections (200U) versus placebo (saline) injections in&#xD;
      the treatment of OAB secondary to benign prostatic obstruction (BPO).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overactive bladder is a common problem that follows chronic prostatic bladder outlet&#xD;
      obstruction and is part of the benign prostatic hyperplasia syndrome (BPH) in men.&#xD;
      Unfortunately, it does not often resolve after treatment (TURP, etc) of the obstruction from&#xD;
      enlarged prostate gland. Patients with obstructive BPH typically commence treatment with&#xD;
      alpha-blockers or anticholinergic agents; the former being used to treat enlarged prostate&#xD;
      medically, and the latter to treat overactive bladder symptoms. However, as mentioned,&#xD;
      anticholinergics cause many intolerable side effects leading to discontinuation in many&#xD;
      patients. Furthermore this class of drug is still considered a relative contraindication in&#xD;
      this population by some clinicians. Therefore other modalities need to be studied in these&#xD;
      men.&#xD;
&#xD;
      Based on numerous studies in overactive bladder (OAB), we hypothesize that these patients&#xD;
      will experience significant improvement (particularly if their symptoms of urgency and&#xD;
      frequency) without significant side effects from intradetrusor injections of BOTOX® even&#xD;
      though they have were refractory to systemic anticholinergics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <completion_date type="Anticipated">May 2007</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and efficacy of BOTOX to placebo (saline) in the treatment of OAB secondary to BPO.</measure>
    <time_frame>6 months post injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction to intradetrussor injection of Botox versus placebo.</measure>
    <time_frame>6 months post injection</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Overactive Bladder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botox</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male between 40 and 90 years of age.&#xD;
&#xD;
          2. Clinical signs and symptoms of frequency and urgency&#xD;
&#xD;
          3. Urodynamic history consistent with OAB that developed in conjunction with Benign&#xD;
             Prostate Obstruction and that persists for at least 3 months post TURP or PVP, or&#xD;
             other obstruction relieving procedure.&#xD;
&#xD;
          4. OAB inadequately controlled with anticholinergic medications&#xD;
&#xD;
          5. Qmax &gt;12mL/s with a voided volume of &gt;125mL.&#xD;
&#xD;
          6. IPSS &gt;12, with IPSS QoL &gt;3 at study Visit 1.&#xD;
&#xD;
          7. Willing to use clean intermittent catheterization (CIC) to empty the bladder or is&#xD;
             willing to have an indwelling catheter, if necessary following study treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known history of interstitial cystitis, uninvestigated hematuria, bladder outlet&#xD;
             obstruction due to vesical neck contracture, mullerian duct cysts, urethral&#xD;
             obstruction due to stricture/valves/sclerosis of urethral tumor, radiation cystitis,&#xD;
             genitourinary tuberculosis, bladder calculi, or detrusor-sphincter dyssynergia.&#xD;
&#xD;
          2. Current indwelling catheter, or removal of chronic catheter &lt;1 month prior to study&#xD;
             entry.&#xD;
&#xD;
          3. Non-compliance with wash-out periods for prohibited medications/therapies&#xD;
&#xD;
          4. Evidence of Urinary Tract Infection according to local standard of care.&#xD;
&#xD;
          5. History of prostate cancer.&#xD;
&#xD;
          6. Serum PSA of &gt;10ng/mL. [NOTE: Subjects with serum PSA concentrations &gt;4 and &lt;10 must&#xD;
             have prostate cancer excluded according to the local standard of care.]&#xD;
&#xD;
          7. 24 hour total volume voided &gt;3000 mL of urine&#xD;
&#xD;
          8. Medical condition that may increase their risk of exposure to botulinum toxin&#xD;
             including diagnosed Myasthenia Gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral&#xD;
             Sclerosis or any other disease that might interfere with neuromuscular function.&#xD;
&#xD;
          9. Allergy or sensitivity to any component of BOTOX®&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonard S Marks, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Urological Sciences Research Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leonard S Marks, M.D.</last_name>
    <phone>(310) 838-6347</phone>
    <email>lsmarks@ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Malu Macairan, M.D.</last_name>
    <phone>(310) 838-6347</phone>
    <email>mmacairan@usrf.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Urological Sciences Research Foundation</name>
      <address>
        <city>Culver City</city>
        <state>California</state>
        <zip>90232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malu Macairan, M.D.</last_name>
      <phone>310-838-6347</phone>
      <email>mmacairan@usrf.org</email>
    </contact>
    <contact_backup>
      <last_name>Anthony Cancio</last_name>
      <phone>(310) 838-6347</phone>
      <email>acancio@usrf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Leonard S Marks, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.usrf.org</url>
    <description>Related Info</description>
  </link>
  <verification_date>January 2007</verification_date>
  <study_first_submitted>May 25, 2007</study_first_submitted>
  <study_first_submitted_qc>May 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2007</study_first_posted>
  <last_update_submitted>May 29, 2007</last_update_submitted>
  <last_update_submitted_qc>May 29, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2007</last_update_posted>
  <keyword>Overactive Bladder</keyword>
  <keyword>OAB</keyword>
  <keyword>Refractory OAB</keyword>
  <keyword>Botox</keyword>
  <keyword>Bladder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

